Related references
Note: Only part of the references are listed.A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behcet's syndrome
Noe Horiguchi et al.
SCIENTIFIC REPORTS (2020)
Ten-Year Retention Rate of Infliximab in Patients with Behcet's Disease-Related Uveitis
Claudia Fabiani et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2019)
Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behcet's disease
Atsuko Katsuyama et al.
CLINICAL OPHTHALMOLOGY (2019)
Predictors of sustained clinical response in patients with Beh double dagger et's disease-related uveitis treated with infliximab and adalimumab
Claudia Fabiani et al.
CLINICAL RHEUMATOLOGY (2018)
Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behcet's disease
Sho Ueda et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2018)
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice A Nationwide Cohort Study From Sweden
Hjalmar Wadstroem et al.
JAMA INTERNAL MEDICINE (2017)
Behcet's disease ocular attack score 24 and visual outcome in patients with Behcet's disease
Rie Tanaka et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Behcet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab
Toshikatsu Kaburaki et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2014)
Evaluation of the Long-Term Efficacy and Safety of Infliximab Treatment for Uveitis in Behcet's Disease
Masaru Takeuchi et al.
OPHTHALMOLOGY (2014)
Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis
Thierry Dervieux et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Long-term Clinical Outcomes in Patients with Refractory Uveitis Associated with Behcet Disease Treated with Infliximab
Sultan Al Rashidi et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2013)
Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease
Hiroshi Goto
ARCHIVES OF OPHTHALMOLOGY (2012)
Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy A Meta-analysis
Maria A. Lopez-Olivo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Long-Term Efficacy and Safety of Infliximab in the Treatment of Behcet's Disease
Maria Jose Capella et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2012)
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behcet's disease
Toshikatsu Kaburaki et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2010)
TNF alpha blockade in human diseases: An overview of efficacy and safety
Jan Lin et al.
CLINICAL IMMUNOLOGY (2008)
Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study
L. Niccoli et al.
RHEUMATOLOGY (2007)
Infliximab treatment for ocular and extraocular manifestations of Behcet's disease
Massimo Accorinti et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2007)
Uveitis in Behcet disease: An analysis of 880 patients.
I Tugal-Tutkun et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2004)
Share Paper
